S. G. Zlotin et al.
FULL PAPER
Tetrahedron: Asymmetry 1997, 8, 3801–3805; d) R. Chenevert,
M. Desjardins, Can. J. Chem. 1994, 72, 2312–2317.
a) M. Hayashi, K. Ogasawara, Heterocycles 2003, 59, 785–791;
b) S. Yoshifuji, M. Kaname, Chem. Pharm. Bull. 1995, 43,
1302–1306; c) C. Herdeis, H. P. Hubmann, Tetrahedron: Asym-
metry 1992, 3, 1213–1221; d) A. Armstrong, N. J. Convine,
M. E. Popkin, Synlett 2006, 1589–1591; e) D. Enders, O. Nie-
meier, Heterocycles 2005, 66, 385–403; f) P. Camps, D. Munoz-
Torrero, L. Sanchez, Tetrahedron: Asymmetry 2004, 15, 2039–
2044; g) E. Licandro, S. Maiorana, C. Baldoli, L. Capella, D.
Perdicchia, Tetrahedron: Asymmetry 2000, 11, 975–980; h) P.
Resende, W. P. Almeida, F. Coelho, Tetrahedron: Asymmetry
1999, 10, 2113–2118; i) N. Langlois, N. Dahuron, H.-S. Wang,
Tetrahedron 1996, 52, 15117–15126; j) A. Schoenfelder, A.
Mann, S. Le Coz, Synlett 1993, 1, 63–65; k) S. Bellemin-La-
ponnaz, J. Tweddell, J. C. Ruble, F. M. Breitling, G. C. Fu,
Chem. Commun. 2000, 1009–1011.
a) A. S. Paraskar, A. Sudalai, Tetrahedron 2006, 62, 4907–4916;
b) T. Nemoto, L. Jin, H. Nakamura, Y. Hamada, Tetrahedron
Lett. 2006, 47, 6577–6581; c) J.-M. Becht, O. Meyer, G.
Helmchen, Synthesis 2003, 18, 2805–2811; d) O. Belda, S.
Lundgren, C. Moberg, Org. Lett. 2003, 5, 2275–2278; e) V. V.
Thakur, M. D. Nikalje, A. Sudalai, Tetrahedron: Asymmetry
2003, 14, 581–586; f) M. P. Doyle, W.-H. Hu, Chirality 2002,
14, 169–172; g) C. Baldoli, S. Maiorana, E. Licandro, D. Per-
dicchia, B. Vandoni, Tetrahedron: Asymmetry 2000, 11, 2007–
2014.
a) T. Okino, Y. Hoashi, T. Furukawa, X. Xu, Y. Takemoto, J.
Am. Chem. Soc. 2005, 127, 119–125; b) E. J. Corey, F.-Y.
Zhang, Org. Lett. 2000, 2, 4257–4259; c) P. Garcia-Garcia, A.
Ladepeche, R. Halder, B. List, Angew. Chem. Int. Ed. 2008, 47,
4719–4721; d) Y. Hayashi, T. Itoh, M. Ohkubo, H. Ishikawa,
Angew. Chem. Int. Ed. 2008, 47, 4722–4724; e) Y. Chi, L. Guo,
N. A. Kopf, S. H. Gellman, J. Am. Chem. Soc. 2008, 130, 5608–
5609; f) J. Vesely, G.-L. Zhao, A. Bartoszewicz, A. Córdova,
Tetrahedron Lett. 2008, 49, 4209–4212; g) B. Vakulya, S. Varga,
T. Soós, J. Org. Chem. 2008, 73, 3475–3480; h) P. S. Hynes,
P. A. Stupple, D. J. Dixon, Org. Lett. 2008, 10, 1389–1391; i)
L. Ji, Y. Ma, J. Li, L. Zhang, L. Zhang, Tetrahedron Lett. 2009,
50, 6166–6168.
dried with MgSO4. The solvent was removed under reduced pres-
sure to afford compound (S)-12 or (R)-12.
[11]
Supporting Information (see footnote on the first page of this arti-
cle): Procedures for preparation of all compounds; 1H, 13C, 19F,
and 31P NMR spectra and HPLC chromatograms.
Acknowledgments
We gratefully acknowledge financial support of the Russian Foun-
dation of Basic Research (grants No. 09-03-00384 and 09-03-
12164).
[1] a) J. G. Hardman, L. E. Limbird, G. A. Gilman (Eds.), Good-
man and Gilman’s The Pharmacological Basis of Therapeutics,
10th ed., McGraw-Hill, New York, 2001, section III; b) P. L.
McGeer, E. G. McGeer in Basic Neurochemistry: Molecular,
Cellular and Medical Aspects (Eds.: G. J. Siegel, B. Agranoff,
R. W. Albens, P. Molinoff), 4th ed., Raven, New York, 1989.
[2] P. Krogsgaard-Larsen, J. Scheel-Krueger, H. Kofod (Eds.),
GABA-Neurotransmitters. Pharmacochemical, Biochemical and
Pharmacological Aspects, Munksgaard, Copenhagen, 1979.
[3] V. E. Shashoua, J. N. Jacob, R. Ridge, A. Campbell, R. J. Bal-
dessarini, J. Med. Chem. 1984, 27, 659–664.
[4] a) G. Costantino, A. Macchiarulo, A. E. Guadix, R. Pellicciari,
J. Med. Chem. 2001, 44, 1827–1832; b) D. I. B. Kerr, J. Ong,
Drug Discovery Today 1996, 1, 371–380; c) W. Froestl,
N. G. Cooke, S. J. Mickel in The Receptors: The GABA Recep-
tors (Eds.: S. J. Enna, H. Möhler), 3rd ed., Humana Press Inc.,
Totowa, 2007, pp. 239–251.
[5] a) H. R. Olpe, H. Demieville, V. Baltzer, W. L. Bencze, W. P.
Koella, P. Wolf, H. L. Haas, Eur. J. Pharmacol. 1978, 52, 133–
136; b) N. G. Bowery, D. R. Hill, A. L. Hudson, Neuropharma-
cology 1985, 24, 207–210; c) N. G. Bowery, A. L. Hudson,
G. W. Price, Neuroscience 1987, 20, 365–383; d) S. Shuto, N.
Shibuty, S. Yamada, T. Ohkura, R. Kimura, A. Matsuda,
Chem. Pharm. Bull. 1999, 47, 1188–1192.
[6] a) D. E. Griswold, E. F. Webb, J. Breton, J. R. White, P. J. Mar-
shall, T. J. Torphy, Inflammation 1993, 17, 333–344; b) H.
Wachtel, Neuropharmacology 1983, 22, 267–272; c) S. J. Kanes,
J. Tokarczyk, S. J. Siegel, W. Bilker, T. Abel, M. P. Kelly, Neuro-
science 2007, 144, 239–246; d) Z. Lelkes, P. Alföldi, A. ErdЈS,
G. Benedek, Pharmacol. Biochem. Behav. 1998, 60, 835–839.
[7] a) L. J. Crofford, M. C. Rowbotham, P. J. Mease, J. I. Russell,
R. H. Dworkin, A. E. Corbin, J. P. Young Jr., L. K. LaMo-
reaux, S. A. Martin, U. Sharma, Arthritis & Rheumatism 2005,
52, 1264–1273; b) P. J. Siddall, M. J. Cousins, A. Otte, T. Gries-
ing, R. Chambers, T. K. Murphy, Neurology 2006, 67, 1792–
1800; c) R. H. Dworkin, P. Kirkpatrick, Nat. Rev. Drug Discov-
ery 2005, 4, 455–456.
[8] a) I. Lapin, CNS Drug Rev. 2001, 7, 471–481; b) J. Ong, D. I. S.
Kerr, D. J. Doolette, R. K. Duke, K. N. Mewett, R. D. Allen,
G. A. R. Johnston, Eur. J. Pharmacol. 1993, 233, 169–172; c)
I. A. Sytinsky, A. T. Soldatenkov, A. Lajtha, Prog. Neurobiol.
1978, 10, 89–96.
[9] For more active (R)-Rolipram, see: a) Ch. A. Parker, J. C. Mat-
thews, R. N. Gunn, L. Martarello, V. J. Cunningham, D. Dom-
mett, S. T. Knibb, D. Bender, S. Jakobsen, J. Brown, A. D. Gee,
Synapse 2005, 55, 270–279; for more active (R)-Balcofen, see:
b) D. F. Smith, J. Neural Transmission 1984, 60, 63–67; for
more active (S)-Pregabalin, see: c) J. E. Frampton, R. H. Fos-
ter, CNS Drugs 2006, 20, 685–693; for more active (R)-Pheni-
but, see: d) M. Dambrova, L. Zvejniece, E. Liepinsh, H. Cirule,
O. Zharkova, G. Veinberg, I. Kalvinsh, Eur. J. Pharm. 2008,
583, 128–134.
[12]
[13]
[14]
[15]
[16]
[17]
[18]
C. Palomo, A. Landa, A. Mielgo, M. Oiarbide, A. Puente, S.
Vera, Angew. Chem. Int. Ed. 2007, 46, 8431–8435.
L. Zu, H. Xie, H. Li, J. Wang, W. Wanga, Adv. Synth. Catal.
2007, 349, 2660–2664.
H. Gotoh, H. Ishikawa, Y. Hayashi, Org. Lett. 2007, 9, 5307–
5309.
Y. Wang, P. Li, X. Liang, T. Y. Zhang, J. Ye, Chem. Commun.
2008, 1232–1234.
a) M. Gruttadauria, F. Giacalone, R. Noto, Chem. Soc. Rev.
2008, 37, 1666–1688; b) M. Lombardo, C. Trombini, ChemCat-
Chem 2010, 2, 135–145.
a) P. Li, L. Wang, M. Wang, Y. Zhang, Eur. J. Org. Chem.
2008, 1157–1160; b) E. Alza, X. C. Cambeiro, C. Jimeno,
M. A. Pericàs, Org. Lett. 2007, 9, 3717–3720; c) Y.-B. Zhao, L.-
W. Zhang, L.-Y. Wu, X. Zhong, R. Li, J.-T. Ma, Tetrahedron:
Asymmetry 2008, 19, 1352–1355; d) M. C. Varela, S. M. Dixon,
K. S. Lam, N. E. Schore, Tetrahedron 2008, 64, 10087–10090;
e) E. Alza, M. A. Pericàs, Adv. Synth. Catal. 2009, 351, 3051–
3056.
a) L. Tuchman-Shukrona, M. Portnoy, Adv. Synth. Catal. 2009,
351, 541–546; b) G. Lv, R. Jin, W. Mai, L. Gao, Tetrahedron:
Asymmetry 2008, 19, 2568–2572; c) Y. Li, X.-Y. Liu, G. Zhao,
Tetrahedron: Asymmetry 2006, 17, 2034–2039.
a) L. Zu, J. Wang, H. Li, W. Wang, Org. Lett. 2006, 8, 3077–
3079; b) L. Zu, H. Li, J. Wang, X. Yu, W. Wang, Tetrahedron
Lett. 2006, 47, 5131–5134.
a) B. Ni, Q. Zhang, K. Dhungana, A. D. Headley, Org. Lett.
2009, 11, 1037–1040; b) D. Q. Xu, Sh. P. Luo, Y. F. Wang, A. B.
Xia, H. D. Yue, L. P. Wang, Zh. Y. Xu, Chem. Commun. 2007,
4393–4395; c) L.-Y. Wu, Z.-Y. Yan, Y.-X. Xie, Y.-N. Niu, Y.-
[19]
[20]
[21]
[22]
[10] a) F. Felluga, V. Gombac, G. Pitacco, E. Valentin, Tetrahedron:
Asymmetry 2005, 16, 1341–1345; b) C. Mazzini, J. Lebreton, V.
Alphand, R. Furstoss, Tetrahedron Lett. 1997, 38, 1195–1196;
c) E. Brenna, N. Caraccia, C. Fuganti, D. Fuganti, P. Grasselli,
2932
www.eurjoc.org
© 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2010, 2927–2933